Hadassah

Hadassah Heart Specialists Reveal Detrimental Effect of Thyroid Imbalance on Heart Failure Patients

Wednesday, Apr 23 2014


A study by the Hadassah Medical Organization's heart specialists has revealed that increased levels of thyroid-stimulating hormone (TSH) are correlated with "worse clinical outcome" in patients suffering from heart failure. "Thyroid imbalance," they report, "confers significant risk in heart failure and warrants attention." While it has been known that thyroid dysfunction affects cardiac function and is a risk factor for heart failure, the scientists report, "data regarding the clinical significance of TSH levels alone as a predictor of outcome in patients with heart failure is sparse." Their study evaluated the significance of TSH on clinical outcome in a large cohort of patients with chronic heart failure.

Study findings reveal that both a high and a low TSH level are associated with an increased mortality rate. In addition, TSH was also an independent predictor of death and cardiac-related hospitalization. For those patients not receiving thyroid hormone treatment, "TSH was an even stronger predictor of mortality." At the same time, increasing TSH levels above normal were "independently associated with increased mortality and cardiac-related hospitalizations." The study, entitled "The Effect of Thyroid Function on Clinical Outcome in Patients with Heart Failure," was published in the February 2014 issue of the European Journal of Heart Failure (Volume 16, Issue 2).

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Monday, May 7 2018

Hadassah Cardiac Specialists Are Collaborating with Colleagues to Save Syrian Children

In an effort to save the lives of Syrian children suffering from life-threatening and complex heart abnormalities, the Hadassah Medical Organization and the Baruch Padeh Medical Center in Poriya-Tiberias have launched a unique collaboration as part of the Israel Defense Forces’ Good Neighbor program.

READ MORE ›
alt_text

Monday, May 7 2018

Pluristem Stem Cell Therapy, Based on Hadassah Preclinical Research, Has Been Cleared by FDA

Pluristem Therapeutics has announced that its new cell therapy to treat acute radiation syndrome (PLX-R18), based on the pioneering studies performed within the laboratory of Prof. Raphael Gorodetsky at the Hadassah Medical Organization, has received clearance from the United States Food and Drug Administration to treat individuals who may have been acutely exposed to high-dose radiation as the result of a nuclear attack or accident.

READ MORE ›
alt_text

Thursday, May 3 2018

HMO Exclusive Call with Nurse Rely Alon

Please join us for an exclusive conference call with Dr. Rely Alon, Director, Division of Nursing & Health Professions, Wednesday May 9, 2018 from 10:00 - 11:00 am EDT

READ MORE ›
alt_text

Tuesday, Apr 17 2018

Predicting Clinical Outcomes for Multiple Sclerosis Patients: Cutting-Edge Research at Hadassah

More than two million people--two to three times more women--have multiple sclerosis (MS)--the leading cause of neurological disability among young adults. What is their prognosis?

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More